{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:31:07Z","timestamp":1777329067923,"version":"3.51.4"},"reference-count":130,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The ubiquitous, early\u2010stage expression, efficient internalization, limited off\u2010target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti\u2010CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B\u2010cell non\u2010Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti\u2010CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B\u2010cell lymphoma and consider approaches to the use of anti\u2010CD19 therapy.<\/jats:p>","DOI":"10.1002\/hon.3013","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T14:33:14Z","timestamp":1651329194000},"page":"505-517","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeting CD19 in diffuse large B\u2010cell lymphoma: An expert opinion paper"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9363-267X","authenticated-orcid":false,"given":"Sarah","family":"Bailly","sequence":"first","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9matologie Cliniques Universitaires Saint\u2010Luc  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"Department of Haematology Centre Hospitalier Universitaire de Montpellier UMR\u2010CNRS 5535  Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridhar","family":"Chaganti","sequence":"additional","affiliation":[{"name":"Department of Haematology Queen Elizabeth Hospital  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-8836","authenticated-orcid":false,"given":"Raul","family":"C\u00f3rdoba","sequence":"additional","affiliation":[{"name":"Department of Hematology Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital Health Research Institute IIS\u2010FJD  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori University of Milan  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"D\u00fcll","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II Universit\u00e4tsklinikum W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9867-8335","authenticated-orcid":false,"given":"Isacco","family":"Ferrarini","sequence":"additional","affiliation":[{"name":"Department of Medicine Section of Hematology University of Verona  Verona Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7383-3001","authenticated-orcid":false,"given":"Wendy","family":"Osborne","sequence":"additional","affiliation":[{"name":"Newcastle Upon Tyne Hospitals NHS Foundation Trust  Newcastle UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7282-8374","authenticated-orcid":false,"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[{"name":"Institute of Pathology University of W\u00fcrzburg, and Comprehensive Cancer Center Mainfranken  W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-6538","authenticated-orcid":false,"given":"Juan\u2010Manuel","family":"Sancho","sequence":"additional","affiliation":[{"name":"ICO\u2010IJC\u2010Hospital Germans Trias I Pujol  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-5246","authenticated-orcid":false,"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[{"name":"Department of Hematology and U1245 Centre Henri Becquerel and University of Rouen  Rouen France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-4185","authenticated-orcid":false,"given":"Eric","family":"Van Den Neste","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9matologie Cliniques Universitaires Saint\u2010Luc  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-6327","authenticated-orcid":false,"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III University Hospital Ulm  Ulm Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-0883","authenticated-orcid":false,"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[{"name":"Department of Medicine Section of Hematology University of Verona  Verona Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228553"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa\u20102018\u20100049"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201003\u2010769620"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.12.001"},{"key":"e_1_2_11_6_1","volume-title":"B\u2010cell Non\u2010hodgkin\u2019s Lymphoma \u2013 Epidemiology Forecast to 2027","author":"Globaldata","year":"2019"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/jbm.s190784"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102004\u201003\u20101110"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201003\u2010276246"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa011795"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(13)60313\u2010x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15412"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010017\u20100612\u2010x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010019\u201003853\u20101"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201018\u20103270"},{"key":"e_1_2_11_17_1","first-page":"145","volume-title":"Aggressive Lymphomas","author":"Nowakowski G","year":"2019"},{"key":"e_1_2_11_18_1","volume-title":"Phase III Study Shows Roche's Polivy Plus R\u2010CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care","author":"Roche","year":"2021"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010020\u201001011\u2010z"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.01.010"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1928074"},{"issue":"2","key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4049\/jimmunol.143.2.712","article-title":"Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily","volume":"143","author":"Tedder TF","year":"1989","journal-title":"J Immunol"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/2162\u20103619\u20101\u201036"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1385\/ir:31:2:119"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1074\u20107613(00)80418\u20105"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa051568"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.11.019"},{"issue":"9","key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.4049\/jimmunol.149.9.2841","article-title":"The CD19\/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody\u20101 and Leu\u201013 molecules","volume":"149","author":"Bradbury LE","year":"1992","journal-title":"J Immunol"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.4.1407"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.8.4062"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201005\u2010718395"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201000"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201011\u20100485"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2004.03.003"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.21338"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s45957"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.828354"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1074\u20107613(00)00007\u20108"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102913"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2015.01.008"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib9040063"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201008\u20102268"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102009\u201006\u2010229039"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.131.4.1789"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010124297"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30225\u20104"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy056"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.7513"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.5363"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7540"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201008\u2010593269"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279802"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010122573"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.8020"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001405\u2010w"},{"key":"e_1_2_11_56_1","volume-title":"MONJUVI\u00ae (Tafasitamab\u2010cxix) Prescribing Information","author":"Morphosys US Inc. and Incyte Corporation","year":"2020"},{"key":"e_1_2_11_57_1","volume-title":"Minjuvi Summary of Product Characteristics","author":"European Medicines Agency","year":"2021"},{"key":"e_1_2_11_58_1","volume-title":"Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R\u2010CHOP in Patients with Newly Diagnosed DLBCL","author":"Clinicaltrials.gov","year":"2020"},{"key":"e_1_2_11_59_1","volume-title":"Tafasitamab + Lenalidomide + R\u2010CHOP versus R\u2010CHOP in Newly Diagnosed High\u2010Intermediate and High Risk DLBCL Patients (frontMIND)","author":"Clinicaltrials.gov","year":"2021"},{"key":"e_1_2_11_60_1","volume-title":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed\/refractory (R\/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)","author":"Clinicaltrials.gov","year":"2021"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1783442"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201006\u2010651380"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.1586"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s202746"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1759055"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000025"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010018\u20103497\u20100"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201010\u2010813493"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201019\u20100711"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000767"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1703531"},{"key":"e_1_2_11_73_1","article-title":"Efficacy and safety of loncastuximab teserine (ADCT\u2010402) in relapsed\/refractory diffuse large B\u2010cell lymphoma","author":"Caimi FP","year":"2020","journal-title":"Poster presented at: 62nd American Society of Hematology Annual Meeting"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.89_2880"},{"key":"e_1_2_11_75_1","article-title":"Interim results of loncastuximab teserine combined with ibrutinib in diffuse large B\u2010cell lymphoma or mantle cell lymphoma (LOTIS\u20103)","author":"Depaus J","year":"2020","journal-title":"Poster presented at: 62nd American Society of Hematology Annual Meeting"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102020\u2010136614"},{"key":"e_1_2_11_77_1","volume-title":"Study to Evaluate Loncastuximab Tesirine with Rituximab versus Immunochemotherapy in Participants with Relapsed or Refractory Diffuse Large B\u2010Cell Lymphoma (LOTIS 5)","author":"Clinicaltrials.gov","year":"2020"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2152\u20102650(21)01894\u20102"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007512"},{"key":"e_1_2_11_80_1","volume-title":"FDA Grants Accelerated Approval to Loncastuximab Tesirine\u2010Lpyl for Large B\u2010Cell Lymphoma","author":"United States Food and Drug Administration","year":"2021"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719841581"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2019.08.003"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(18)30864\u20107"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1804980"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(20)31366\u20100"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25951"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02104"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000186"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/2155179018822781"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010020\u20100956\u20108"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2018.01.025"},{"key":"e_1_2_11_93_1","volume-title":"Expanding CAR\u2010T Manufacturing in Europe to Serve More Patients","author":"Novartis","year":"2020"},{"key":"e_1_2_11_94_1","volume-title":"Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe","author":"Gilead","year":"2021"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010123656"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26301"},{"key":"e_1_2_11_97_1","volume-title":"YESCARTA\u00ae (Axicabtagene Ciloleucel) Suspension for Intravenous Infusion Prescribing Information","author":"Kite Pharma, Inc"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010129532"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25411"},{"key":"e_1_2_11_100_1","article-title":"Outcome of high\u2010grade lymphoma patients treated with CD19 CAR\u2010T \u2012 updated real\u2010world experience in the UK","author":"Kuhnl A","year":"2020","journal-title":"Abstract presented at: 25th European Haematology Association Annual Congress"},{"issue":"21","key":"e_1_2_11_101_1","first-page":"00851","article-title":"Patterns and predictors of failure in recurrent or refractory large B\u2010cell lymphomas following chimeric antigen receptor (CAR) T\u2010cell therapy","volume":"0360","author":"Figura NB","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001837"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010129107"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5283"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003001"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010930"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001370\u20104"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010019\u201002635\u20109"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00146"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1884677"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102020\u2010140314"},{"key":"e_1_2_11_112_1","volume-title":"Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects with Relapsed\/Refractory Diffuse Large B Cell Lymphoma (ZUMA\u20107)","author":"Clinicaltrials.gov","year":"2020"},{"key":"e_1_2_11_113_1","volume-title":"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High\u2010Risk, Transplant\u2010Eligible Relapsed or Refractory Aggressive B\u2010Cell Non\u2010hodgkin Lymphomas (TRANSFORM)","author":"Clinicaltrials.gov","year":"2021"},{"key":"e_1_2_11_114_1","volume-title":"Tisagenlecleucel in Adult Patients with Aggressive B\u2010Cell Non\u2010Hodgkin Lymphoma (BELINDA)","author":"Clinicaltrials.gov","year":"2020"},{"key":"e_1_2_11_115_1","volume-title":"Lisocabtagene Maraleucel (JCAR017) as Second\u2010Line Therapy (TRANSCEND\u2010PILOT\u2010017006)","author":"Clinicaltrials.gov","year":"2018"},{"key":"e_1_2_11_116_1","volume-title":"Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects with Relapsed\/Refractory Diffuse Large B Cell Lymphoma (ZUMA\u20107)","author":"ClinicalTrials.gov","year":"2021"},{"key":"e_1_2_11_117_1","volume-title":"Kite Announces Yescarta\u00ae CAR T\u2010Cell Therapy Improved Event\u2010free Survival by 60% over Chemotherapy Plus Stem Cell Transplant in Second\u2010Line Relapsed or Refractory Large B\u2010Cell Lymphoma","year":"2021"},{"key":"e_1_2_11_118_1","volume-title":"Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (Lisocabtagene Maraleucel) versus Chemotherapy Followed by Stem Cell Transplant in Second\u2010Line Relapsed or Refractory Large B\u2010Cell Lymphoma","year":"2021"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17384"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01467"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010129371"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002587"},{"key":"e_1_2_11_123_1","article-title":"Experience of prior anti\u2010CD19 therapy in patients with relapsed or refractory large B\u2010cell lymphoma receiving lisocabtagene maraleucel (liso\u2010cel), and investigational anti\u2010CD19 chimeric antigen receptor T cell product","author":"Solomon S","year":"2021","journal-title":"Poster presented at: Transplantation & Cellular Therapy Meetings"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2021.100260"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1986219"},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201015\u20101020"},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.9b00808"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.57"},{"key":"e_1_2_11_129_1","article-title":"Expression of CD19 antigen on chronic lymphocytic leukemia cells after tafasitamab (anti\u2010CD19) treatment: phase 1 trial data","author":"Boxhammer R","year":"2020","journal-title":"Poster presented at: 25th European Haematology Association Annual Congress"},{"key":"e_1_2_11_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.201"},{"key":"e_1_2_11_131_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02664"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3013","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.3013","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T05:21:03Z","timestamp":1695878463000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/hon.3013"],"URL":"https:\/\/doi.org\/10.1002\/hon.3013","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"2022-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}